Press Release Archive
Press Releases
December 2023
12.09.2023 Marstacimab Phase 3 Data Presented at ASH 2023 Demonstrate Significant Bleed Reduction in Hemophilia A and B 12.08.2023 European Commission Approves Pfizer’s ELREXFIO® for Relapsed and Refractory Multiple Myeloma 12.05.2023 Corporate Partnerships Arvinas and Pfizer Announce Interim Data from Phase 1b Trial of Vepdegestrant in Combination with Palbociclib (IBRANCE®) and Plans to Expand Vepdegestrant Development Program 12.04.2023 Corporate Partnerships Pfizer and Valneva Complete Recruitment for Phase 3 VALOR Trial for Lyme Disease Vaccine Candidate, VLA15 12.01.2023 Pfizer Announces Topline Phase 2b Results of Oral GLP-1R Agonist, Danuglipron, in Adults with Obesity
November 2023
11.28.2023 Corporate Medicines Arvinas and Pfizer Announce Updated Vepdegestrant (ARV-471) Data to be Presented at the 2023 San Antonio Breast Cancer Symposium 11.21.2023 Financial Finance Pfizer Invites Public to View and Listen to Webcast of Pfizer Discussion at Healthcare Conference 11.16.2023 Corporate Medicines Pfizer and Astellas' XTANDI® Approved by U.S. FDA in Earlier Prostate Cancer Treatment Setting 11.02.2023 Research and Pipeline Research Pfizer Highlights Scientific Advances from Growing Hematology Portfolio at American Society of Hematology Annual Meeting 11.02.2023 Financial Finance Pfizer Invites Public to View and Listen to Webcast of Pfizer Discussion at Healthcare Conference 11.01.2023 Corporate Partnerships Stanford Medicine Launches New Global Health Scholars Program for African Physicians
October 2023
10.31.2023 Pfizer Reports Third-Quarter 2023 Results
Media Resources & Contact Information
Anyone may view our press releases, press statements, and press kits.
However, to ensure that customers, investors, and others receive the appropriate attention, Pfizer media contacts may only respond to calls and emails from professional journalists.